Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose related and decline on smoking cessation

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 11, 2000, Pages 1211-1214

  Scott, David A ^a   Stapleton, John A ^b   Palmer, Richard M ^a   Wilson, Ron F ^a   Gustavsson, Gunnar ^b,c   Coward, Paula Y ^a   Odell, Edward W ^a   Poston, Robin N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATORY DISEASE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SMOKING CESSATION;

ADULT; AGED; ANTIGENS, CD44; BIOLOGICAL MARKERS; CARBON DIOXIDE; COTININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION;

EID: 0033730327     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. CD44v(3, 8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
2. Adhesion proteins in the biology of breast cancer: Contribution of CD44
3. Expression of CD44s, CD44v5, CD44v6 and CD44v7-8 in betel quid chewing-associated oral premalignant lesions and squamous cell carcinomas in Taiwan
4. CD44 in inflammation and metastasis
5. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs
6. Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas
7. CD44 isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor
8. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumour invasion
9. Potential use of soluble CD44 in serum as an indicator of tumour burden and metastasis in patients with gastric or colon cancer
10. Soluble CD44 splice variants in metastasizing human breast cancer
11. CD44: Structure, function and association with the malignant process
12. Elevated serum CD44 level is associated with unfavourable outcome in non-Hodgkin's lymphoma
13. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer
14. Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis
15. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis
16. IgG, albumin and sCD44 in whole gut lavage fluid are useful clinical markers for assessing the presence and activity of pouchitis
17. Evaluation of soluble CD44 in the BALF before and after treatment of DPB (diffuse panbronchitis) with macrolide antibiotics
18. Serum concentration of total soluble CD44 is elevated in smokers
19. Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking
20. Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients
21. CD44v6 expression in inflammatory bowel disease is associated with activity detected by endoscopy and pathological features
22. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma
23. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma
24. Evaluation of the prognostic value of serum soluble CD44 in patients with breast cancer
25. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma
26. High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer
27. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial
28. The CD44 protein family
29. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons